and motor neurone disease (MND) symposia this fall. "These important meetings bring together the leading ALS researchers, clinicians, care providers, drug developers, and industry partners from ...

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for ...

The findings could lead to development of therapies to prevent or slow the progression of ALS early on, before major damage has been done. The study was published on October 31, 2024 in Neuron. A ...

Of the 91 patients originally diagnosed with PMA, 20 subsequently developed upper motor neuron signs, which would qualify them as having ALS with lower motor neuron onset. Furthermore, upper motor ...

--(BUSINESS WIRE)--Aclipse Therapeutics LLC (“Aclipse” or “the Company”) today announced that its M102 drug development program has been selected for presentations at the premier amyotrophic lateral ...

M102 takes a broad mechanistic approach to treat the complexity of ALS (also known as Motor Neurone Disease ... patient stratification approaches for sporadic ALS patients that may allow for ...

Summary: Researchers have uncovered a mechanism that may trigger ALS’s earliest stages, identifying proteins that mislocalize, causing neuron degeneration. By targeting the RNA-binding protein SmD1, ...

Diagnosed with amyotrophic lateral sclerosis (ALS), the disease not only affected Kerner's mobility but also her ability to speak. However, thanks to artificial intelligence technology ...